Anika Therapeutics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Anika Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Anika Therapeutics: 5 sponsored US clinical trials, 1 recruiting.
Anika Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Defect of Articular Cartilage, with 1 trials.
Upper-quartile sponsor footprint
Anika Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527
HyaloFAST Trial for Repair of Articular Cartilage in the Knee
NCT02659215
Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
NCT04231318
Safety Study of Cosmetic Tissue Augmentation in People of Color
NCT01147172
Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee
NCT00653432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where Anika Therapeutics enrollment is open (later-stage tilt)
1 recruiting of 5 indexed (20% open); 3 completed (60%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Defect of Articular Cartilage (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Anika Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Anika Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Anika Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Anika Therapeutics or any single study.
- 1 of Anika Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Defect of Articular Cartilage is the condition Anika Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Defect of Articular Cartilage trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Anika Therapeutics pipeline card: 5 registered trials from official public datasets.Report a data error.